Navigation Links
Factors linked to speech/swallowing problems after treatment for head and neck cancers
Date:12/20/2010

DURHAM, NC Most patients with locally advanced head and neck cancers who successfully complete treatment with chemotherapy and radiation manage to do so without losing the ability to speak clearly and swallow comfortably, according to researchers at the Duke Cancer Institute.

"This is good news," said Joseph K. Salama, MD, an assistant professor of radiation oncology at Duke and the corresponding author of the study. "I hope it brings some comfort to newly-diagnosed patients who are understandably worried about what long-term effects treatment might involve."

The study findings appear in the Dec. 20 issue of the Archives of Otolaryngology & Head and Neck Surgery.

The American Cancer Society estimates that more than 70,000 people will develop some form of head and neck cancer in the coming year. The malignancies are regarded as some of the most burdensome because they can be so disruptive to normal pleasures of life such as talking and eating. In addition, surgical treatment can dramatically alter facial structure, striking at the most visible aspect of identity.

"Surprisingly, there are few studies of this size and duration that have followed these patients and documented in detail factors that alter their functional status after organ preserving therapy," said Salama.

Working with colleagues at the University of Chicago, Salama conducted a retrospective study of 184 patients with advanced but treatable head or neck cancers enrolled in a phase II trial. All received about two months of chemotherapy with carboplatin and paclitaxel and then additional chemotherapy along with radiation over a ten-week period. Some of the patients also underwent minor surgery to remove simple tumors or lymph nodes in their necks.

Using a four-point scale, researchers evaluated the patients' ability to speak and swallow anywhere from six weeks to six years after all treatments had ended. The average time that patients were evaluated was three years post-treatment. They found that 85 percent of the patients were able to speak normally and 63 percent were able to swallow normally.

Among those who did not fare as well, several factors stood out. Generally, older patients did worse than younger ones. A history of smoking and the presence of tumors located directly on or near the larynx were also linked with poorer speech post-treatment. The study also showed that women generally had poorer speech than men, but Salama says that this may reflect the inclusion of far fewer women than men in the study.

Factors associated with worse swallowing outcomes included age, poor overall health, the specific area where the cancer appeared and planned surgery on the neck following the completion of chemotherapy and radiation therapy.

Researchers also found that patients with better long-term speaking and swallowing were more likely to have better swallowing before and shortly after treatment.

"This suggests that early evaluation post treatment may be a good tool for doctors and patients to use to predict the possibility of long-term problems," said Salama.


'/>"/>

Contact: Michelle Gailiun
michelle.gailiun@duke.edu
919-660-1306
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. Fox Chase researchers uncover new risk factors for brain metastases in breast cancer patients
2. HFES announces Release of Reviews of Human Factors and Ergonomics, Volume 6
3. Fox Chase researchers identify risk factors for the spread of breast cancer to lymph nodes
4. Childhood stroke study identifies the contraceptive pill and smoking as risk factors
5. Study identifies 5 risk factors for late-stage head and neck cancer
6. Hospital readmission studies: Influencing factors identified
7. Lifestyle intervention improves risk factors in type 2 diabetes
8. MSU researcher awarded $14 million to identify breast cancer risk factors
9. 4 possible risk factors for ovarian cancer found
10. Benefits of healthy lifestyle factors stronger in combination
11. New study singles out factors linked to cognitive deficits in type 2 diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
Breaking Medicine Technology: